Skelegen is an orthopaedic biotechnology startup company that is developing novel tissue engineering strategies to promote bone regeneration for clinical indications including fractures, segmental defects, spinal fusion, and dental and craniofacial reconstruction. The company, established in November 2012, was created based on technology developed in Professor Kurt Hankenson's laboratory at the University of Pennsylvania in collaboration with his former graduate student Michael Dishowitz. Their technology utilizes a novel osteoinductive protein called Jagged1, a ligand in the Notch signaling pathway, that induces differentiation of stem cells into osteoblasts, which are bone-producing cells. The product in development is comprised of Jagged1 and a scaffold biomaterial that allows for localized and targeted protein delivery to areas in need of bone regeneration. Their technology is patent pending.
Kurt Hankenson, Ph.D
Assistant Professor of Cell Biology, Laboratories of Anatomy
School of Veterinary Medicine, University of Pennsylvania
Michael Dishowitz, Ph.D
Graduate from the Department of Bioengineering
School of Engineering and Applied Science, University of Pennsylvania